soul trial oral semaglutide cardiovascular outcomes results 2024 2025 align more closely with attained dose than achieved weight loss Cardiovascular outcomes of semaglutide and
Pay in 4 interest-free payments of $7.12 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6
Live Spec
Cardiovascular outcomes of semaglutide and tirzepatide for patients with type 2 diabetes in clinical practice Nature Medicine Clinical Effectiveness and Safety of Oral Semaglutide in a Real World Cohort of Patients with Heart Failure with Reduced Ejection Fraction, Type 2 Diabetes and Obesity: A Propensity Score Matched Analysis Targeting the weight within: obesity pharmacotherapy in cardiovascular disease Medicine Today Cardiovascular Outcomes Associated with Semaglutide in Type 2 Diabetes: A Systematic Review and Meta Analysis Oral Semaglutide Reduces CV Events in T2DM SOUL Trial (NEJM, Mar 2025) Relevant for: cardiology, diabetology, nephrology, internal medicine T2DM + ASCVD CKD Oral semaglutide 14 mg vs placebo Oral semaglutide reduces risk of cardiovascular events Drug Discovery World (DDW)
Store: skntheory.com · Domain: skntheory.com




























